Analysts expect 20/20 Biolabs (AIDX) to report Q2 2026 revenue of approximately $0.89 million and a consensus EPS loss of $0.06, with the current share price of $0.55 trading significantly below the average analyst price target of $5.00.
The primary focus for investors is the commercial expansion of OneTest™, the company’s AI-powered multi-cancer early detection blood test, particularly its adoption in high-volume municipal firefighter screening programs.
This reporting period follows significant contract wins in Vermont and Maryland, where the company is providing screenings for thousands of first responders. Furthermore, shareholders are closely monitoring the company's liquidity runway after a recent Series E preferred stock financing and the total elimination of its convertible debt.